Evidence map›Paper›PMID 41134321›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT.

Guozhu Hou, Yuanyuan Jiang, Yi Yang, Susheng Shi, Yihebali Chi, Rong Zheng, Hong Zhao, Jingjing Zhang, Xuejuan Wang

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guozhu Hou *Department of Nuclear Medicine (PET-CT Center), National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yuanyuan Jiang *Department of Nuclear Medicine (PET-CT Center), National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yi YangDepartment of Hepatobiliary Surgery, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Susheng ShiDepartment of Pathology, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Yihebali ChiDepartment of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Rong ZhengDepartment of Nuclear Medicine (PET-CT Center), National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hong ZhaoDepartment of Hepatobiliary Surgery, National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. zhaohong@cicams.ac.cn.
Jingjing ZhangDepartment of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore. j.zhang@nus.edu.sg.ORCID 0000-0002-6948-1813
Xuejuan WangDepartment of Nuclear Medicine (PET-CT Center), National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. xuejuan_wang@hotmail.com.

Funding

National University of Singapore NUHSRO/2021/097/Startup/13
6 · The paper itself

Abstract

Radiolabeled somatostatin receptor (SSTR) analogues are widely utilized for both imaging (PET or scintigraphy) and peptide receptor radionuclide therapy (PRRT) in the management of neuroendocrine neoplasms (NENs). These approaches have been extensively validated in low- to intermediate-grade gastroenteropancreatic neuroendocrine tumors (NET G1 - G2). However, data on the use of SSTR imaging - particularly SSTR PET imaging - in patients with high-grade NETs (G3) and neuroendocrine carcinomas (NECs) remain limited. This study aimed to evaluate the diagnostic performance of ¹⁸F-AlF-NOTA-octreotide (¹⁸F-AlF-OC) PET/CT in patients with high-grade NENs and assess its complementarity with ¹⁸F-FDG PET/CT.

methodsOut of 426 patients who underwent ¹⁸F-AlF-OC PET/CT between January 2023 and October 2024, 42 patients with histologically confirmed high-grade NENs (28 with G3 NETs and 14 with NECs) were retrospectively analyzed. 36 patients also underwent

resultsOn a per-patient basis, ¹⁸F-AlF-OC PET/CT was positive in 39 of 42 patients, yielding a detection rate of 92.9%. Among all patients, 28 (66.7%, 28/42) exhibited high ¹⁸F-AlF-OC uptake, and 19 (45.2%, 19/42) demonstrated positivity in all lesions. Of the 36 patients who underwent both scans, detection rates were 91.7% (33/36) for ¹⁸F-AlF-OC and 88.9% (32/36) for ¹⁸F-FDG PET/CT. Discordant findings were observed in 11 patients (30.6%) with¹⁸F-AlF-OC-negative/¹⁸F-FDG-positive lesions and in 13 patients (36.1%) with ¹⁸F-AlF-OC-positive/¹⁸F-FDG-negative lesions. On a per-lesion basis, ¹⁸F-AlF-OC PET/CT showed a higher detection rate than ¹⁸F-FDG PET/CT (80.7% [547/678] vs. 72.9% [494/678]). Specifically, ¹⁸F-AlF-OC identified 109 lesions missed by ¹⁸F-FDG, while ¹⁸F-FDG identified 56 lesions missed by ¹⁸F-AlF-OC. The combined use of both tracers improved the detection rate to 89.1% (604/678), surpassing either modality alone.

conclusion¹⁸F-AlF-OC PET/CT demonstrated high detection rates in patients with high-grade NENs, with a substantial proportion showing strong SSTR expression and lesion-wide positivity, supporting its potential role in guiding PRRT eligibility. The complementary nature of ¹⁸F-AlF-OC and ¹⁸F-FDG PET/CT enhances overall diagnostic accuracy, making dual-tracer imaging a valuable approach in this setting.

Indexed as

Carcinoma, NeuroendocrineFluorodeoxyglucose F18Heterocyclic Compounds, 1-RingNeuroendocrine TumorsOctreotidePositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm GradingRetrospective StudiesFluorodeoxyglucose F18Heterocyclic Compounds, 1-RingOctreotide18F-AlF-NOTA-octreotide18F-FDGG3 NETsHigh-grade NENsPETPRRT

Identifiers

PMID41134321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.